##  [Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL](/us-en/news/media-releases/novartis-highlights-new-ctl019-phase-ii-data-demonstrating-93-complete-remission-pediatric-patients-rr-all-0 "Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL") 

  Dec 07, 2015